GET DAILY SIGNALSMilestone Pharmaceuticals (MIST) Declines -13.1% Over 30 Days as Pipeline Advances
Key Takeaways
- Milestone Pharmaceuticals (MIST) declined roughly 13.1% over the trailing 30 days, moving from about $0.80 to near $0.69 per share.
- The pullback extends a longer slide, with shares down approximately 35% over the last quarter from the low-$1 range.
- Milestone is an emerging commercial-stage biopharmaceutical company led by CARDAMYST (etripamil) nasal spray, which is FDA-approved for paroxysmal supraventricular tachycardia (PSVT).
- The decline has continued despite steady clinical progress, including the first European patient enrollment in the Phase 3 ReVeRA-301 trial for atrial fibrillation with rapid ventricular rate (AFib-RVR).
- Regulatory milestones such as the China NMPA approval of etripamil and rising U.S. commercial insurance coverage have not yet reversed the selling pressure.
- For additional context, review the ticker's Price Targets, Earnings, and Forecast pages.
Company Background and Market Position
Milestone Pharmaceuticals Inc. focuses on developing and commercializing cardiovascular medicines. Its lead asset, CARDAMYST (etripamil) nasal spray, is a rapid-onset calcium channel blocker approved by the FDA for converting acute episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The self-administered nasal spray allows patients to manage episodes outside a hospital setting.
The company is also advancing etripamil in a Phase 3 program (ReVeRA-301) for atrial fibrillation with rapid ventricular rate (AFib-RVR) and in Phase 2 for pediatric PSVT. In September 2026, China’s National Medical Products Administration approved etripamil for PSVT, with partner Everest Medicines handling commercialization in Greater China. Investors track MIST for its U.S. launch progress, expansion into the larger AFib market, and path to revenue growth.
Stock Price Performance Over the Past 30 Days and Quarter
Over the trailing 30 days, MIST fell approximately 13.1%, declining from a closing level near $0.80 in late September to roughly $0.69 per share in the most recent completed session. The path was uneven: the stock drifted lower through early-to-mid October, briefly touched the low-$0.60 range, and rebounded about 7.8% in the most recent session.
The quarterly picture shows a steeper drop. From the start of the quarter near $1.07, MIST has fallen roughly 35%. This reflects a persistent multi-month downtrend rather than an isolated event, with the steepest portion occurring during September as the stock broke below $1.00 and continued lower into October.
What Influenced the 30-Day Move
The recent decline unfolded against a backdrop of incremental pipeline updates rather than major breakthroughs. In early October, Milestone announced the first European patient enrolled in ReVeRA-301, its Phase 3 pivotal trial of etripamil for AFib-RVR, through the Dutch Cardiovascular Investigator Network. The company also plans to present data at cardiology conferences including TCT and the American Heart Association Scientific Sessions. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Despite these steps, selling pressure persisted. As an emerging commercial-stage company with limited near-term revenue, MIST remains sensitive to small-cap biotech sentiment and concerns around clinical and financing timelines. No single negative catalyst stands out; instead, investors appear to be weighing dilution and cash-burn considerations against the longer-term AFib-RVR opportunity.
Drivers Behind the Quarterly Decline
The broader quarterly drop reflects a repricing that began in late summer. During the period, Milestone started and advanced ReVeRA-301, with U.S. enrollment beginning in August 2026 and expansion to Canada at the Montreal Heart Institute. Second-quarter results noted that more than 50% of commercially insured lives in the U.S. now have access to CARDAMYST. The China NMPA approval added geographic reach, yet attention stayed on the pace of the U.S. launch and the timeline to a supplemental new drug application for AFib-RVR. Persistent risk-off sentiment in small-cap biotech and lower trading liquidity contributed to the steady downward path.
Key Factors to Watch Going Forward
Several elements will likely shape MIST’s path ahead. Prescription growth for CARDAMYST and further payer coverage expansion remain central to the commercial story, along with revenue per prescription as free-drug programs taper. On the clinical side, ReVeRA-301 enrollment progress and data readouts for the AFib-RVR indication represent the largest potential value drivers given the bigger addressable population. Investors should also follow upcoming conference presentations, quarterly results and cash runway updates, and any news on the single-study sNDA pathway. Macro conditions and risk appetite for small-cap biotech names may continue to influence near-term trading. From what I see, execution risk, regulatory outcomes, and financing needs stay important to monitor.
Using AI Tools for Additional Perspective
In my research, I often review Tickeron’s AI Trading Bots to compare systematic strategies across biotech names like MIST. The platform surfaces a range of automated approaches with different styles and timeframes, helping me evaluate how algorithmic models are positioned amid current market conditions. This adds a useful layer of data-driven context alongside fundamental analysis without replacing my own due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MIST's Stochastic Oscillator is remaining in oversold zone for 5 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +3.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIST advanced for three days, in 220 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
MIST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MIST as a result. In 69 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for MIST turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 41 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for MIST entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.724) is normal, around the industry mean (3.037). P/E Ratio (-1.063) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (44.843) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. MIST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MIST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer and manufacturer of cardiovascular medicines
Industry Biotechnology
Advertisement